Advertisement


Claus Garbe, MD, Summarizes Results of the DECOG Trial on SLNB-Positive Melanoma

2015 ASCO Annual Meeting

Advertisement

Claus Garbe, MD, of the University of Tuebingen, discusses the survival of sentinel lymph node biopsy–positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).



Related Videos

Breast Cancer

Richard G. Margolese, MD, and Robert W. Carlson, MD, on NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Robert W. Carlson, MD, of the National Comprehensive Cancer Network, and Richard G. Margolese, MD, of McGill University, discuss the improvement in breast cancer–free interval with anastrozole vs tamoxifen in patients with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract LBA500).

Skin Cancer

Claus Garbe, MD, and Anthony J. Olszanski, RPh, MD, on The DECOG Trial on Sentinel Lymph Node–Positive Melanoma

Claus Garbe, MD, of the University of Tuebingen, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss the survival of sentinel lymph node-positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).

Colorectal Cancer

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).

Prostate Cancer

Nicholas David James, MD, PhD, and Celestia S. Higano, MD, on Results From the STAMPEDE Trial on Hormone-Naive Prostate Cancer

Celestia S. Higano, MD, of the University of Washington, and Nicholas David James, MD, PhD, of Warwick Medical School, discuss data showing improvements in survival from adding docetaxel in men starting long-term hormone therapy for the first time (Abstract 5001).

Lung Cancer

Luis G. Paz-Ares, MD, PhD, Summarizes Results of the CheckMate 057 Trial on Nonsquamous Cell NSCLC

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario Doce De Octubre, discusses the superior overall survival in patients taking nivolumab vs docetaxel in advanced nonsquamous NSCLC (Abstract LBA109).

Advertisement

Advertisement



Advertisement